• Este endereço de email está protegido contra piratas. Necessita ativar o JavaScript para o visualizar.

Artigos Científicos

quinta-feira, 07 março 2019 17:06

Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial

Rate this item
(0 votes)

Robert L. Findling, Lenard A. Adler, Thomas J. Spencer, Robert Goldman, Seth C. Hopkins, Kenneth S. Koblan, Justine Kent, Jay Hsu, and Antony Loebel

Journal of Child and Adolescent Psychopharmacology 

7 Mar 2019


Abstract:

Purpose: Dasotraline is a potent inhibitor of presynaptic dopamine and norepinephrine reuptake with a pharmacokinetic profile characterized by slow absorption and a long elimination half-life. The aim of this study was to evaluate the efficacy and safety of dasotraline in children with attention-deficit/hyperactivity disorder (ADHD).

METHODS: Children aged 6–12 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of ADHD were randomized to 6 weeks of double-blind once-daily treatment with dasotraline (2 or 4 mg) or placebo. The primary efficacy endpoint was change from baseline in the ADHD Rating Scale Version IV–Home Version (ADHD RS-IV HV) total score at week 6.

RESULTS: A total of 342 patients were randomized to dasotraline or placebo (mean age 9.1 years, 66.7% male). Treatment with dasotraline was associated with significant improvement at study endpoint in the ADHD RS-IV HV total score for the 4 mg/day dose versus placebo (−17.5 vs. −11.4; p < 0.001; effect size [ES], 0.48), but not for the 2 mg/day dose (−11.8 vs. −11.4; ns; ES, 0.03). A regression analysis confirmed a significant linear dose–response relationship for dasotraline. Significant improvement for dasotraline 4 mg/day dose versus placebo was also observed across the majority of secondary efficacy endpoints, including the Clinical Global Impression (CGI)–Severity score, the Conners Parent Rating Scale-Revised scale (CPRS-R) ADHD index score, and subscale measures of hyperactivity and inattentiveness. Discontinuation rates due to adverse events (AEs) were higher in the dasotraline 4 mg/day group (12.2%) compared with the 2 mg/day group (6.3%) and placebo (1.7%). The most frequent AEs associated with dasotraline were insomnia, decreased appetite, decreased weight, and irritability. Psychosis-related symptoms were reported as AEs by 7/219 patients treated with dasotraline in this study. There were no serious AEs or clinically meaningful changes in blood pressure or heart rate on dasotraline.

CONCLUSIONS: In this placebo-controlled study, treatment with dasotraline 4 mg/day significantly improved ADHD symptoms and behaviors, including attention and hyperactivity, in children aged 6–12 years. The most frequently reported AEs observed on dasotraline included insomnia, decreased appetite, decreased weight, and irritability.

Ver artigo completo...


A Direção da SPDA - Sociedade Portuguesa de Défice de Atenção 

Read 68 times Last modified on segunda-feira, 03 fevereiro 2020 11:46
© 2020 SPDA - Sociedade Portuguesa de Défice de Atenção. All Rights Reserved. Design by BID-lab